As early diagnosis and therapies of breast cancer have improved, more than 2.2 million women are now breast cancer survivors in the United States. This increase in survival, however, raises the likelihood that patients will experience side-effects of anti-cancer therapies, notably cardiotoxicity.
The cardiotoxicity of anthracyclines is well recognized. Trastuzumab increases the cardiotoxicity of anthracyclines treatment, with left ventricular (LV) dysfunction noted in as many as a third of the patients and an incidence of congestive heart failure of 2-5% in patients treated with both therapies 1 . Although the decrease in LV ejection fraction (LVEF) appears to be responding to treatment in a majority of patients 2 , its long-term prognosis is unknown.
Left ventricular ejection fraction, which is widely used to monitor cardiac systolic function after chemotherapy fails to detect subtle alterations in LV function. Once the LVEF has decreased in patients treated with anthracyclines, it may be too late to reverse the course of the cardiomyopathy 3 . More sensitive and specific markers of chemotherapy-induced cardiac dysfunction or myocardial injury may allow for earlier and better adaptations of oncologic and cardiac treatments.
Evidence is accumulating that recently developed echocardiographic indices and biomarkers may be useful in the detection of early cardiac injury. Decreases in myocardial strain and strain rate have been described after anthracyclines -based chemotherapies [4] [5] [6] [7] [8] . In a preliminary study, we reported that in a small cohort of patients treated with anthracyclines, taxanes and trastuzumab, measurements of peak longitudinal systolic strain at 3 months of follow-up predicted a decrease in LVEF 3 months later 8 . The longer term predictive value of these measures in a larger cohort, and the optimum measurement time point remain to be determined.
pr pr pr pr pr pr prog og og og og og ogno no no no no no nosi si si si si si sis s s s s s s is is is is is is is u u u u u u unk nk nk nk nk nk nk ular ejection fraction, which is widely used to monitor cardia o c s e More sensitive and specific markers of chemotherapy-induced ular ejection fraction, which is widely used to monitor cardia otherapy fails to detect subtle alterations in LV function. Onc s treated with anthracyclines, it may be too late to reverse the More sensitive and specific markers of chemotherapy-induced Troponin measurements have been used to measure myocardial injury and predict incident LV dysfunction in patients receiving high doses of anthracyclines, 9 but their role in patients receiving low to moderate doses of anthracyclines is not established 10 . Importantly, the studies reporting predictive values of noninvasive measurements included patients with multiple treatments and at different stages during their therapies. This heterogeneity has not allowed for the differentiation of the role of the various therapies on myocardial function, and has limited the clinical use of the measurements.
The primary objective of this prospective study was to assess whether LVEF, myocardial strain, and biomarkers of cardiac injury (troponin), wall stress (NT-proBNP) and remodeling (NT-proBNP, ST2) obtained early in the course of the treatment in a homogeneous cohort of women with newly diagnosed HER2 positive breast cancer treated with anthracyclines followed by taxanes and trastuzumab could predict subsequent cardiotoxicity occurring throughout the full course of the treatment. Another objective of the study was to investigate the time course of these imaging and blood markers throughout the treatment. For the models predicting cardiotoxicity, we a priori selected to study the value of the parameters obtained at the completion of the anthracyclines treatment, before taxanes and trastuzumab were introduced, as anthracyclines have been shown to induce more severe cardiotoxicity than either taxanes or trastuzumab.
Methods
Patients of at least 18 years of age newly diagnosed with HER-2 over-expressing breast cancer and scheduled to receive adjuvant therapy including anthracyclines, taxanes, and trastuzumab were eligible. Patients who had a baseline LVEF<50% were excluded.
NT proBNP) a and nd n n n n n in a a ho ho ho ho ho ho homo mo mo mo mo mo moge ge ge ge ge ge gene ne ne ne n n n o After a signed informed consent, patients were studied before chemotherapy, at the completion of anthracyclines therapy (19±9 days after the last anthracyclines cycle) and every 3 months subsequently until the end of the trastuzumab treatment (12 months in duration), for a total of 6 studies over 15 months ( Figure 1 ). Each study visit included a detailed questionnaire including the presence of cardiac symptoms, an echocardiogram and blood sampling.
The primary endpoint was the occurrence of cardiotoxicity as defined by the Cardiac Review and Evaluation Committee of trastuzumab-associated cardiotoxicity (CREC) i.e. either a cardiomyopathy with decreased LVEF, a reduction of LVEF of 5% to less than 55% with symptoms of heart failure (diagnosed by a cardiologist at the site) or an asymptomatic reduction of LVEF of 10% to less than 55% 11 .
Echocardiograms
Transthoracic echocardiograms were acquired using the Vivid 7 or E9 (GE Healthcare, Milwaukee, WI). The same ultrasound machine was used to acquire all echocardiograms in each patient. All echocardiograms were analyzed by 2 readers (MS-C for the LVEF, HS for all other measurements). The readers were blinded to each other's measurements and to the patient visit number. LVEF was calculated from the apical 4-and 2-chamber views using a modified Simpson's biplane method. The intraobserver variability of the LVEF reported as the mean error ± SD of 10 measurements was 1±5% in absolute values (1±8% in percentages) and the interobserver variability -2±5% in absolute values (-4±8% in percentages). Peak systolic strain was measured using speckle tracking (Echopac, GE Medical, Milwaukee, WI), at a frame rate of 80-100 fps. Peak systolic radial and circumferential strain was calculated by averaging the peak 5% to less tha ha ha ha ha ha han ) or a a a a a an n n n n n n as as as as as as sym ym ym ym ym ym ympt pt pt pt pt p pto o o o less than 55% 11 .
systolic strain values in all 6 segments of the parasternal short-axis view at midpapillary level.
Peak systolic longitudinal strain was calculated by averaging the values of peak systolic strain in the basal and mid-ventricular segments of the 4-and 2-chamber views 8 . The intra-and interobserver variabilities of the strain in the laboratory were reported in a previous study 8 .
Biomarkers
Troponin I was determined using a research-phase highly sensitive assay based on LOCI® technology and run on a Dimension Vista 1500® System (Siemens Healthcare Diagnostics).
This ultrasensitive troponin I (usTnI) assay has a range of 0.5-20,000 pg/mL and a 10% % coefficient of variation (CV) of 3 pg/mL. All values of troponin I of more than 30 pg/ml (95 th percentile of values obtained before treatment) were considered elevated.
NT-proBNP was measured on the Dimension Vista® 500 Intelligent Laboratory System
(Siemens Healthcare Diagnostics, Deerfield, IL). The limit of detection of NT-proBNP assay is 0.8 pg/mL. The highest value of NT-proBNP reported in healthy subjects of less than 75 years of age is 125 pg/mL thus all values of NT-proBNP of more than 125 pg/mL were considered elevated.
ST2 was measured using a research use only assay (Presage ST2, Critical Diagnostics, San Diego, CA) on an automated enzyme linked-immunosorbent assay platform. This assay has been reported to have an inter-run CV of 2.0%, with values below 35 pg/mL considered normal 12 .
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Statistics
The study was designed as a prospective multicenter study. The primary aim was to test the association between echocardiographic markers of systolic function and biomarkers (predictors) and subsequent occurrence of cardiotoxicity (outcome). Based on our previous study in which the sensitivity of deformation measurements in the prediction of LV dysfunction in mice was 95% 4 , and assuming a rate of cardiotoxicity of 25% in patients 13 Statistical analyses were performed using JMP statistical package (SAS Institute In. Cary, NC). Data are expressed as mean ± SD or median with interquartile range.
Results

Population
The enrollment and completion of the study are summarized on Figure 2 . Eighty-one patients completed the study. Of these patients, 12 had partial follow-up (average of 4.9±0.3 visits) but did not differ from the rest of the cohort. Patients were treated with either doxorubicin (cumulative dose of 240 mg/m 2 ) or epirubicin (cumulative dose of 300 mg/m 2 ) for 3 months, followed by weekly paclitaxel (80 mg/m 2 ) and trastuzumab (2mg/kg) for 3 months, and trastuzumab only (6mg/kg) every 3 weeks for 9 more months. Their baseline clinical characteristics are presented in Table 1 .
Effect of chemotherapy and trastuzumab on LVEF
The mean LVEF decreased during treatment (from 64±5 to 59±6%, Table 2 , Figure 3A the women who developed cardiotoxicity compared to the ones who did not (Table 1 ). In women developing cardiotoxicity, the decrease in LVEF was detected most frequently 3 months after the end of the anthracyclines therapy (11 patients), less commonly early (n=3), 6 months (n=5), 9 months (n=5), and 12 months (n=2) after the end of anthracyclines.
The mean decrease in LVEF in patients with CREC-defined cardiotoxicity was partially reversible (49 ± 4% at the nadir to 56 ± 7% at the end of the follow-up, P<0.0001). The 
Effect of chemotherapy and trastuzumab on myocardial strain and biomarkers
Peak systolic longitudinal myocardial strain decreased during the study period (from 21±2% to 19±2%, Table 2 , Figure 3B , p < 0.0001 over the duration of the study). In women who developed cardiotoxicity, the mean longitudinal strain decreased to a nadir of 15 ± 3%. Both radial and circumferential components of the strain also decreased (p < 0.005 for radial and p < 0.02 for circumferential strain over the duration of the study). Ultrasensitive TnI concentrations increased during the follow-up period (from a median of 1.3 pg/ml to 23 pg/ml, p<0.0001, Table 3 , Figure 3C ) and were highest at the completion of the anthracyclines treatment. In women who developed cardiotoxicity, the usTnI concentrations at completion of anthracyclines were 32 pg/ml [10-56 pg/ml] whereas they were 17 pg/ml pg/ml] in women who did not (p=0.18). NT-proBNP levels and ST2 levels did not change significantly throughout follow-up (Table 3) .
Predictive value of strain and biomarkers in the development of cardiotoxicity
The predictive value of parameters measured at the completion of anthracyclines therapy and of the changes of these parameters compared to baseline was studied. For these analysis, the 3 patients who had already developed cardiotoxicity at the completion of anthracyclines were excluded, thus the analysis was done on 23 cases of cardiotoxicity. LVEF. Left ventricular ejection fraction measured at the com risk of developing cardiotoxicity 8 . Longitudinal strain <19% was measured in 74% of the patients developing cardiotoxicity subsequently (sensitivity, Table 4 ). Fifty-three percent of patients with strain <19% developed cardiotoxicity during follow-up (positive predictive value, Table 4 ). In contrast, 13% of the patients with longitudinal strain >19% at completion of the anthracyclines treatment developed cardiotoxicity. Of note, longitudinal strain measured at the completion of the anthracyclines treatment predicted decreases of LVEF to less than 50% (p < 0.0001). Neither radial nor circumferential strain were predictive of subsequent cardiotoxicity (p = 0.25 and p = 0.67, respectively).
Predictive value of biomarkers. None of the biomarkers were predictive of cardiotoxicity when measured as continuous variables. However, elevated usTnI concentrations (>30 pg/ml) at the completion of the anthracyclines treatment were predictive of subsequent cardiotoxicity (p = 0.04, Table 4 ). Neither elevated NT-proBNP nor ST2 were predictive of later cardiotoxicity (p = 0.39 and p = 0.78, respectively).
Multivariate analysis.
When longitudinal strain and usTnI were included in a multivariate analysis adjusted for age and the presence of hypertension, longitudinal strain <19% remained the only independent predictor of cardiotoxicity (p = 0.0003).
Clinical symptoms. Five patients developed symptoms of heart failure during the course of the study (6%). One patient presented at the completion of the anthracyclines treatment, one patient 3 months, two patients 6 months, and one patient 12 months after treatment by anthracyclines. of heart failure (both 6 months later). UsTnI measured 3, 6, 9 months after anthracyclines did not detect any symptomatic patients.
Discussion
In this prospective study of women with breast cancer treated with anthracyclines followed by taxanes and trastuzumab, peak systolic longitudinal myocardial strain and usTnI measured at the completion of anthracyclines therapy were predictive of the development of cardiotoxicity as defined by the CREC during the subsequent treatment course (a period of 12 months after the completion of anthracyclines). A significant decrease of LVEF (8% or more 14 ) was detected at the completion of anthracyclines treatment in only 15% of the patients developing cardiotoxicity during follow-up. In contrast, changes in more sensitive markers of myocardial injury or dysfunction such as troponin or strain were detected at completion of the anthracyclines in 78% of patients developing subsequent cardiotoxicity. Furthermore, longitudinal strain <19% was present in all the patients who later developed symptoms of heart failure.
The present study was designed to investigate a homogeneous population of chemotherapy-treated patients. The women enrolled were representative of a population diagnosed with first time breast cancer, in terms of their age, cardiovascular risk factors cardiovascular and cancer treatments 15 . The applicability of the results to patients treated with anthracyclines, taxanes and trastuzumab was confirmed by the fact that the incidence of CRECdefined cardiotoxicity and symptomatic heart failure were similar to those observed in larger trials 13 . It is noteworthy that the LVEF decreases during the treatment period but remains within normal limits when averaged in the whole group, a finding that has also been reported in large studies 16 . 8% or more ) ) ) ) ) ) ) w Anthracyclines-induced cardiotoxicity is mainly mediated through the generation of reactive oxygen species and is accompanied by increased cardiomyocyte calcium overload and apoptosis, an irreversible process 17 . In contrast, HER2-inhibitors disrupt myofibrillar structure but do not appear to cause extensive cardiomyocyte death 18 In the present study, NT-proBNP concentrations did not change and did not predict cardiotoxicity. Similarly, ST2, a novel marker that is associated with the occurrence of remodeling and heart failure 21 , was unchanged. Of note, the baseline level of ST2 observed in the patients before any cardiotoxic treatment was high compared to the reported median in a healthy population 22 , suggesting that levels may be altered in these patients. Thus, the negative results of NT-proBNP and ST2 may possibly be attributed to the multiple comorbidities found in cancer patients capable of modifying these biomarkers levels 23 .
Cardinale et al. have reported that the measurement of troponin I predicted the development of later cardiac events in patients treated by high doses of anthracyclines 9 or chmotherapies and trastuzumab 24 . The present study confirms the value of measuring troponin in patients with breast cancer treated with anthracyclines, taxanes and trastuzumab and clarifies its optimal timing. Although ultrasensitive troponin was not an independent predictor of later cardiotoxicity, its measurement combined with the measurement of longitudinal strain increased the sensitivity of the biomarkers from 74% to 87%, allowing a negative predictive value of 91%.
Thus, measuring both strain and troponin may be of value in predicting the absence of toxicity of the cancer treatment.
In the present study, few patients had symptoms of heart failure, precluding any analysis of the value of echocardiography and biomarkers in the prediction of symptomatic heart failure.
Peak longitudinal myocardial strain, however, was not only predictive of CREC-defined cardiotoxicity but also of decreases of LVEF to less than 50%. The clinical relevance of such a decrease in LVEF is high; in a study of 4257 participants from the Framingham study, the presence of an asymptomatic LVEF between 40 and 50% was accompanied with a 3.9 risk in heart failure and 1.9 risk in mortality compared to participants with LVEF >50% 25 
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